Most people associate Alzheimer’s disease with an elderly person who can’t recall their grandchildren’s names. The image is too well known since it lacks most of the tale. Forgetting is late. The disease—a biological betrayal of the brain—can start 20–30 years before anyone notices.
One of Alzheimer’s most troubling aspects is the disease symptom gap. Researchers now know that beta amyloid and tau can accumulate in the brain before a person repeats a question, loses their keys, or worries. Plaques form. Tangles form. Synapses break. The guy lives unaware. We may have treated Alzheimer’s too late for decades because we couldn’t notice it until it was too late.
Alzheimer’s disease accounts for most of the UK’s one million dementia cases. People who think of it as a state of bewilderment and care facilities are surprised to learn that it is one of the country’s leading causes of death. Current projections show that the societal cost will more than quadruple by 2040 from £42 billion. That number includes fatigued family members who gave up employment, spouses managing prescriptions at 3am, and adult children navigating a legal system they never expected in their forties.
Alzheimer’s is hard to discuss because most of what people know is wrong. Although age is the biggest risk factor, it is not typical with aging. Despite APOE e4 gene mutations increasing the likelihood, it is not hereditary. Though those are early indicators, it goes beyond forgetting names and losing conversation. And deterioration is not inevitable without intervention. Recently, things have gotten really interesting and difficult at that last point.
Lecanemab and donanemab, monoclonal antibodies that remove beta amyloid from the brain, are novel. In carefully selected early Alzheimer’s patients, both medications reduced decline relative to placebo. Not a minor thing. Science now shows that tackling Alzheimer’s biology can change its trajectory, not merely conceal its symptoms. The weight of decades of unsuccessful studies, billions spent on failed ideas, and families watching and waiting is impossible to ignore. Last, something that works.
With the breakthrough came complications. Both medicines can cause brain swelling or minor bleeding, requiring cautious patient selection and MRI surveillance. Their benefits are small, although participants declined more slowly. NHS funding is a contentious issue. In its 2025 draft guidance, NICE found that the benefit was too small to justify routine NHS use compared to the whole cost of safe delivery infusions, scanning, and specialized oversight. Both assessments are still being appealed and reviewed mid 2026. Inequities come with private access.
A different kind of progress is happening in the background, which may affect how regular people are diagnosed. Large UK clinical trials are testing blood tests for Alzheimer’s pathology, specifically p tau217. ADAPT and READ OUT are testing whether these assessments function reliably in NHS memory clinics across ethnic groupings, income levels, and health histories. The consequences are serious if they can. Most persons treated through conventional NHS paths never undergo a lumbar puncture or a costly PET scan to confirm Alzheimer’s pathology. An easy blood test could transform who gets diagnosed and when.
From the outside, the field seems to be moving faster than the health system can handle. Diagnostic tools, prospective treatments, genetic testing, digital monitoring technologies, and AI supported assessment arrive simultaneously, straining memory clinics and unpaid caretakers. UK government’s £150 million Dame Barbara Windsor Dementia Goals program, Dementia Patient Flow Challenge, and new research networks show intent. Whether intent becomes capacity is uncertain.
Whoever has watched a parent or lover suffer from Alzheimer’s may find the science remote. It matters more immediately whether someone sat with them, played their favorite music, and knew how to speak to them when language started to slide. Life limiting Alzheimer’s remains. That applies regardless of trials. But the understanding of what it is, when it starts, and how it can be slowed is changing, requiring considerable attention and cautious optimism.
i) https://www.england.nhs.uk/long-read/dementia-programme-and-preparation-for-new-alzheimers-disease-modifying-treatments/
ii) https://www.nhs.uk/conditions/alzheimers-disease/treatment/
iii) https://thebelleisle.co.uk/inside-why-low-alcohol-lager-is-suddenly-everywhere-in-portsmouth-pubs/
iv) https://thebelleisle.co.uk/jelena-ostapenko-weight-what-the-numbers-say-and-what-they-dont/